vs
ASP Isotopes Inc.（ASPI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是ASP Isotopes Inc.的1.2倍（$19.6M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs -11.5%），STANDARD BIOTOOLS INC.自由现金流更多（$-23.1M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ASPI vs LAB — 直观对比
营收规模更大
LAB
是对方的1.2倍
$16.7M
营收增速更快
ASPI
高出1307.2%
-11.5%
自由现金流更多
LAB
多$24.3M
$-47.4M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | 12.5% | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | 1295.7% | -11.5% |
| 净利润同比 | -586.8% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPILAB
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | $19.6M | ||
| Q2 25 | — | $21.8M | ||
| Q1 25 | — | $40.8M | ||
| Q3 24 | — | $22.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | — | $45.5M | ||
| Q4 23 | — | $28.2M |
净利润ASPILAB
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | $-34.7M | ||
| Q2 25 | — | $-33.5M | ||
| Q1 25 | — | $-26.0M | ||
| Q3 24 | — | $-26.9M | ||
| Q2 24 | — | $-45.7M | ||
| Q1 24 | — | $-32.2M | ||
| Q4 23 | — | $-19.8M |
毛利率ASPILAB
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% | ||
| Q4 23 | — | 47.6% |
营业利润率ASPILAB
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% | ||
| Q4 23 | — | -75.9% |
净利率ASPILAB
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | -177.4% | ||
| Q2 25 | — | -153.7% | ||
| Q1 25 | — | -63.8% | ||
| Q3 24 | — | -122.0% | ||
| Q2 24 | — | -203.3% | ||
| Q1 24 | — | -70.6% | ||
| Q4 23 | — | -70.2% |
每股收益（稀释后）ASPILAB
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 | ||
| Q4 23 | — | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $129.4M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $399.7M |
| 总资产 | $498.0M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPILAB
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M | ||
| Q4 23 | — | $51.7M |
总债务ASPILAB
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | $63.5M |
股东权益ASPILAB
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | $399.7M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $454.6M | ||
| Q3 24 | — | $489.3M | ||
| Q2 24 | — | $510.3M | ||
| Q1 24 | — | $577.3M | ||
| Q4 23 | — | $-148.1M |
总资产ASPILAB
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | $539.6M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $579.6M | ||
| Q3 24 | — | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | — | $777.7M | ||
| Q4 23 | — | $323.1M |
负债/权益比ASPILAB
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-23.1M |
| 自由现金流率自由现金流/营收 | -284.7% | -118.1% |
| 资本支出强度资本支出/营收 | 57.9% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流ASPILAB
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | $-22.2M | ||
| Q2 25 | — | $-20.7M | ||
| Q1 25 | — | $-30.3M | ||
| Q3 24 | — | $-27.9M | ||
| Q2 24 | — | $-39.0M | ||
| Q1 24 | — | $-62.5M | ||
| Q4 23 | — | $-14.1M |
自由现金流ASPILAB
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M | ||
| Q4 23 | — | $-14.1M |
自由现金流率ASPILAB
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% | ||
| Q4 23 | — | -50.2% |
资本支出强度ASPILAB
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% | ||
| Q4 23 | — | 0.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
